

Special Issue

Combination Therapies in Cancers

Message from the Guest Editor

This Special Issue on “Combination Therapies in Cancers” will address the current efforts and advances in preclinical and clinical studies for the development of combinatorial approaches for effective cancer treatment. Special attention will be on the translation of these findings towards the clinic. The Special Issue will show different perspectives of improving the activity of cancer treatment through the design of combination therapies and the development of combinatorial strategies with other treatment options. Although many questions might remain unanswered, general interest in combination strategies seems to drive the whole field of cancer research. We hope that this Special Issue facilitates recognition and understanding of the power of carefully designed combination treatments. Prof. Dr. Patrycja Nowak-Sliwinska
Prof. Dr. Arjan W. Griffioen

Deadline for manuscript submissions

closed (31 January 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/39224

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)